PD-1 Blockade with Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma: A Multicenter, Single-Arm, Phase 2 Study

• Caesarman E
• Damania B
• Krown SE
• Martin J.
• Bower M
• Whitby D

Kaposi’s sarcoma.

Nat Rev Dis Primers. 2019; 5: 9

• Dupuy S
• Lambert M
• Zucman D
• et al.

Human herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during asymptomatic infection and Kaposi’s sarcoma.

PLoS Pathog. 2012; 8e1002486

• Lebbe C
• Garbe C
• Stratigos AJ
• et al.

Diagnosis and treatment of Kaposi’s sarcoma: European consensus interdisciplinary guide (EDF/EADO/EORTC).

Eur J Cancer. 2019; 114: 117-127

• Regnier-Rosencher E
• Guillot B
• Dupin N.

Treatments for classic Kaposi’s sarcoma: a systematic review of the literature.

J Am Acad Dermatol. 2013; 68: 313-331

• Cianfrocca M
• Lee S
• Von Roenn J.
• et al.

Randomized trial comparing paclitaxel with pegylated liposomal doxorubicin for advanced Kaposi’s sarcoma associated with human immunodeficiency virus: evidence for palliation of symptoms with chemotherapy.

Cancer. 2010; 116: 3969-3977

• Polizotto MN
• Uldrick TS
• Wyvill KM
• et al.

Pomalidomide for symptomatic Kaposi’s sarcoma in HIV-infected and uninfected people: a phase I/II study.

J Clin Oncol. 2016; 34: 4125-4131

• Klémen ND
• Hwang S
• Bradic M
• et al.

Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma.

Clin Cancer Res. 2021; 135244

• Nghiem PT
• Bhatia S
• EJ Lipson
• et al.

PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma.

N Engl J Med. 2016; 374: 2542-2552

• Yarchoan M
• Hopkins A.
• Jaffee EM

Tumor mutational load and response rate to PD-1 inhibition.

N Engl J Med. 2017; 377: 2500-2501

• Beldi-Ferchiou A
• Lambert M
• Dogniaux S
• et al.

PD-1 mediates the functional depletion of activated NK cells in patients with Kaposi’s sarcoma.

Oncocible. 2016; 7: 72961-72977

• Delyon J
• Bizot A
• Battistelle M
• Magdalene I
• Vercellin L
• Lebbe C

PD-1 blockade with nivolumab in endemic Kaposi’s sarcoma.

Anne Oncol. 2018; 29: 1067-1069

• Saller J.
• Walko CM
• Millis SZ
• Henderson-Jackson E
• Makanji R
• Brohl AS

Response to checkpoint inhibitor treatment in advanced classic Kaposi’s sarcoma: about a case and immunogenomic study.

J Natl Compr Canc Netw. 2018; 16: 797-800

• Tabata MM
• Novoa RA
• BUI NQ
• Zaba LC

Successful treatment of HIV-negative Kaposi’s sarcoma with ipilimumab and nivolumab and concurrent management of psoriasis and baseline bullous pemphigoid.

JAAD Case Rep. 2020; 6: 447-449

• Cesmeci E
• Guven DC
• Aktas BY
• Aksoy S

Case of metastatic Kaposi’s sarcoma successfully treated with anti-PD-1 immunotherapy.

J Oncol Pharm Pract. 2021; 27: 1766-1769

• Uldrick TS
• Gonçalves PH
• Abdul Hay M.
• et al.

Safety evaluation of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study.

JAMA Oncol. 2019; 5: 1332-1339

• Rajdev L.
• S-lens
• Ramos JC
• et al.

1023MO AMC 095: A report on nivolumab (nivo) in advanced HIV-associated solid tumors (STs).

Anne Oncol. 2020; 31: S706

• Delyon J
• Layout D
• Baroudjian B
• Lebbe C

Letter to the editor: Could the immunogenicity of Kaposi’s sarcoma be linked more to viral antigens than to tumor mutational burden?.

J Natl Compr Canc Netw. 2018; 16: 1418-1419

• Brambilla L
• Genoese floor
• Berti E
• et al.

Diagnosis and treatment of classic and iatrogenic Kaposi’s sarcoma: Italian recommendations.

Ital J Dermatol Venereol. 2021; 156: 356-365

• Benajiba L
• Lambert J.
• La Selva R
• et al.

Systemic therapeutic initiation in classic and endemic Kaposi’s sarcoma: risk factors and global multi-state modeling in a monocentric cohort study.

Cancers (Basel). 2021; 132519

• Sobngwi E
• Choukem SP
• Agbalika F
• et al.

Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-Saharan Africans.

JAMA. 2008; 299: 2770-2776

• Chowell D
• Krishna C
• Pierini F
• et al.

The evolutionary divergence of the HLA class I genotype has an impact on the efficacy of cancer immunotherapy.

NatMed. 2019; 25: 1715-1720

• Pierini F
• Lenz TL

Advantage of the divergent allele at the level of human MHC genes: signatures of past and current selection.

Mol Biol Evol. 2018; 35: 2145-2158

• Grantham R

Amino acid difference formula to help explain protein evolution.

Science. 1974; 185: 862-864

• Galanina N.
• Goodman AM
• RP Cohen
• Frampton DG
• Kurzrock R

Successful treatment of HIV-associated Kaposi’s sarcoma with immune checkpoint blockade.

Cancer Immunol Res. 2018; 6: 1129-1135

• Delyon J
• Zuber J.
• Dorent R
• et al.

Immune checkpoint inhibitors in transplantation – a case series and comprehensive review of current knowledge.

Transplantation. 2021; 105: 67-78

• Gambichler T
• Susok L

PD-1 blockade for disseminated Kaposi’s sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.

Immunotherapy. 2020; 12: 451-457

• Di Lorenzo G.
• Kreuter A
• Di Trolio R
• et al.

Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of nonvisceral classic Kaposi’s sarcoma: a multicenter study.

J Invest Dermatol. 2008; 128: 1578-1580

• Brambilla L
• Romanelli A.
• Bellinvia M
• et al.

Weekly paclitaxel for advanced classical aggressive Kaposi’s sarcoma: experience of 17 cases.

Br J Dermatol. 2008; 158: 1339-1344

• Fardet L
• Stoebner PE
• Bachelez H
• et al.

Taxane treatment of refractory or life-threatening Kaposi’s sarcoma not associated with human immunodeficiency virus infection.

Cancer. 2006; 106: 1785-1789

• Herbst RS
• Baas P
• Kim DW
• et al.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial.

Lancet. 2016; 387: 1540-1550

• Anderson LA
• Laurie C
• Romano N.
• et al.

Risk factors for classic Kaposi’s sarcoma in a population-based case-control study in Sicily.

Cancer epidemiol biomarkers Prev. 2008; 17: 3435-3443

• Topalian SL
• Hodi FS
• Brahmer JR
• et al.

Safety, activity and immune correlates of anti-PD-1 antibodies in cancer.

N Engl J Med. 2012; 366: 2443-2454

• Country S
• Bagir EK
• Become MA
• Gonlusen G

Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.

Med Oncol. 2016; 33: 93

• Kim Y.J.
• Jung C.J.
• Won the CH
• et al.

Expression of PD-1 and PD-L1 in Kaposi’s sarcoma: a comparative study according to pathological stage and clinical characteristics.

J Cutan Pathol. 2021; 48: 221-228

• Chen B.J.
• Chapuy B
• Ouyang J
• et al.

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Clin Cancer Res. 2013; 19: 3462-3473

• Gambichler T
• Koim S
• Wrobel M
• et al.

Expression of programmed cell death proteins in Kaposi’s sarcoma and cutaneous angiosarcoma.

J Immunother. 2020; 43: 169-174

• Genoese floor
• Venegoni L
• Fanoni D
• Tourlaki A
• Brambilla L
• Berti E

PD-L1 expression in the tumor microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi’s sarcoma.

J Eur Acad Dermatol Venereol. 2019; 33: e269-e271

• Arora J
• Pierini F
• McLaren pajamas
• Carrington M
• Fellay J.
• Lenz TL

The advantage of HLA heterozygotes against HIV-1 is driven by quantitative and qualitative differences in the specific peptide presentation of HLA alleles.

Mol Biol Evol. 2020; 37: 639-650

• Ramasvami R
• Polizotto MN
• Lurain K
• et al.

Safety, activity and long-term results of pomalidomide in the treatment of Kaposi’s sarcoma in people with and without HIV infection.

Clin Cancer Res. 2022; (published online on January 19.)

• Jansen YJL
• Rozeman EA
• Mason R
• et al.

Discontinuation of anti-PD-1 antibody treatment in the absence of disease progression or treatment-limiting toxicity: clinical outcomes in advanced melanoma.

Anne Oncol. 2019; 30: 1154-1161